Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APJ agonist antibody
- Development stage
- Preclinical
- Lead developer
- JiKang Therapeutics
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
APJ agonist antibody is a novel single-domain antibody (nanobody) that acts as a potent agonist of the apelin receptor (APJ). Developed by JiKang Therapeutics, with BioAge Labs holding an exclusive option to in-license the program, the nanobody is reported to be at least 10-fold more potent than apelin, the natural ligand of APJ, with an EC50 comparable to best-in-class small molecule APJ agonists. It is being developed as a long-acting biologic candidate for the treatment of obesity and other metabolic diseases. Preclinical studies have shown that APJ agonism can enhance weight loss when combined with GLP-1 receptor agonists, while also improving muscle function and body composition.
- Other names
- APJ agonist nanobodyJiKang's APJ-agonist nanobody
02
Targets
APLNR (Apelin receptor)
Beyond the preview
Go deeper on APJ agonist antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APJ agonist antibody.